121,989 Kura Oncology, Inc. $KURA Shares Sold by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management cut its Kura Oncology stake by 45.6%, selling 121,989 shares in the third quarter and retaining 145,759 shares valued at approximately $1.56 million.
• Kura shares opened at $9.86, near the lower end of their 52-week range. The company remains unprofitable, though its latest quarterly loss of $0.77 per share beat analyst expectations of $0.88.
• Wall Street’s outlook remains broadly positive: 11 analysts rate Kura a Buy, with a consensus “Moderate Buy” rating and an average price target of $25.35, well above the recent share price.

Assenagon Asset Management S.A. lessened its holdings in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 45.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 145,759 shares of the company's stock after selling 121,989 shares during the period. Assenagon Asset Management S.A. owned about 0.16% of Kura Oncology worth $1,561,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. IFP Advisors Inc grew its holdings in Kura Oncology by 136.5% during the second quarter. IFP Advisors Inc now owns 2,542 shares of the company's stock worth $28,000 after buying an additional 1,467 shares in the last quarter. Allworth Financial LP bought a new position in Kura Oncology during the 2nd quarter valued at $113,000. Pictet Asset Management Holding SA bought a new position in Kura Oncology during the 1st quarter valued at $96,000. E Fund Management Co. Ltd. bought a new position in Kura Oncology during the 2nd quarter valued at $132,000. Finally, WINTON GROUP Ltd boosted its holdings in Kura Oncology by 26.2% during the 2nd quarter. WINTON GROUP Ltd now owns 13,000 shares of the company's stock worth $143,000 after acquiring an additional 2,700 shares during the last quarter.

Kura Oncology Trading Down 0.2%

Shares of NASDAQ:KURA opened at $9.86 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73. The business has a fifty day moving average price of $11.38 and a two-hundred day moving average price of $10.37. Kura Oncology, Inc. has a 1 year low of $7.36 and a 1 year high of $13.90.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.11. The firm had revenue of $20.87 million during the quarter, compared to analyst estimates of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. Sell-side analysts anticipate that Kura Oncology, Inc. will post -3.25 EPS for the current year.

Insider Activity at Kura Oncology

In other Kura Oncology news, insider Francis Burrows sold 20,726 shares of Kura Oncology stock in a transaction dated Thursday, September 24th. The shares were sold at an average price of $10.83, for a total value of $224,462.58. Following the sale, the insider owned 42,327 shares of the company's stock, valued at approximately $458,401.41. The trade was a 32.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Mollie Leoni sold 28,802 shares of Kura Oncology stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $10.75, for a total transaction of $309,621.50. Following the completion of the sale, the insider directly owned 141,095 shares in the company, valued at approximately $1,516,771.25. This represents a 16.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 153,881 shares of company stock valued at $1,708,183 in the last 90 days. 7.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. JPMorgan Chase & Co. began coverage on shares of Kura Oncology in a research note on Thursday, October 1st. They issued an "overweight" rating and a $30.00 target price for the company. Deutsche Bank Aktiengesellschaft set a $24.00 target price on shares of Kura Oncology in a report on Wednesday, October 14th. UBS Group reissued a "buy" rating on shares of Kura Oncology in a research report on Monday, October 5th. Citigroup restated a "market outperform" rating on shares of Kura Oncology in a report on Wednesday, October 14th. Finally, Wedbush upped their price objective on shares of Kura Oncology from $36.00 to $38.00 and gave the stock an "outperform" rating in a research report on Thursday, August 13th. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Kura Oncology currently has a consensus rating of "Moderate Buy" and a consensus target price of $25.35.

Kura Oncology Profile

Kura Oncology, Inc NASDAQ: KURA is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company's research programs target genetic and molecular drivers of malignancies, with the goal of developing therapies for patients with limited treatment options.

Kura's lead product candidate has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia (AML), including AML associated with NPM1 mutations and KMT2A rearrangements.

Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc. (NASDAQ:KURA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.